Supplemental figures and tables

Published benefits of ivermectin use in Itajaí, Brazil for COVID-19 infection, hospitalisation, and mortality are entirely explained by statistical artefacts

Robin Mills Ana Carolina Peçanha Antonio Greg Tucker-Kellogg^{*}

List of Tables

S1	i-ENR model with probabilistic stop on infection. Stop probability: 0.30 (irregu- lar), 0.05 (regular). Statistics for hospitalisations and deaths are reported for all individuals in the cohort.	3
S2	i-ENR model with uniform stop on infection. Stop probability: 1.0 (all individuals).	1
S3	i-ENR model with probabilistic stop on infection. Stop probability: 0.30 (irregular),	4
	individuals	Δ
S 4	i-FNR model with uniform stop on infection. Stop probability: 1.0 (all individuals)	т
•	Statistics for hospitalisations and deaths are limited to infected individuals.	5
S5	i-INF model with probabilistic stop on infection. Stop probability: 0.30 (irregu-	
	lar), 0.05 (regular). Statistics for hospitalisations and deaths are reported for all	
	individuals in the cohort	6
S6	i-INF model with uniform stop on infection. Stop probability: 1.0 (all individuals).	
	Statistics for hospitalisations and deaths are reported for all individuals in the cohort.	7
S7	i-INF model with probabilistic stop on infection. Stop probability: 0.30 (irregular),	
	0.05 (regular). Statistics for hospitalisations and deaths are limited to infected	
	individuals.	7
58	i-INF model with uniform stop on infection. Stop probability: 1.0 (all individuals).	~
60	Statistics for hospitalisations and deaths are limited to infected individuals.	8
39	I-KC22 model with probabilistic stop on infection. Stop probability: 0.30 (irreg-	
	individuals in the schort	0
S10	i-KC22 model with uniform stop on infection. Stop probability: 10 (all individuals)	9
510	Statistics for hospitalisations and deaths are reported for all individuals in the cohort	10
S11	i-KC22 model with probabilistic stop on infection. Stop probability: 0.30 (irregular).	10
5.11	0.05 (regular). Statistics for hospitalisations and deaths are limited to infected	
	individuals.	10

*correspondence to dbsgtk@nus.edu.sg

S12	i-KC22 model with uniform stop on infection. Stop probability: 1.0 (all individuals).	
	Statistics for hospitalisations and deaths are limited to infected individuals	11

List of Figures

S1	"Missed" deaths	12
S2	Attrition bias in the i-INF model	13
S3	Attrition bias in the i-KC22 model	14
S4	Apparent protection of "regular" users in the i-INF model	15
S5	Apparent protection of "regular" users in the i-KC22 model	16

i-ENR model simulations

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.83	0.80-0.88	17%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	0.94	0.88–1.00	6%	0.022	0.68	0.64–0.73	32%	<0.001		
non-user vs regular	0.72	0.64–0.81	28%	<0.001	0.51	0.45–0.57	49%	<0.001		
irregular vs regular	0.77	0.68–0.86	23%	<0.001	0.75	0.66–0.84	25%	<0.001		
Hospitalisation										
non-user vs user	0.75	0.56–1.03	25%	0.039	0.35	0.26–0.47	65%	<0.001		
non-user vs irregular	1.23	0.86–1.76	-23%	0.856	0.52	0.34–0.74	48%	<0.001		
non-user vs regular	0.33	0.06-0.72	67%	0.002	0.00	0.00-0.00	100%	< 0.001		
irregular vs regular	0.27	0.05–0.60	73%	<0.001	0.00	0.00-0.00	100%	<0.001		
Death										
non-user vs user	0.71	0.50–1.02	29%	0.026	0.32	0.23-0.44	68%	<0.001		
non-user vs irregular	1.26	0.84–1.89	-26%	0.837	0.49	0.31–0.74	51%	< 0.001		
non-user vs regular	0.22	0.02-0.57	78%	0.002	0.14	0.00-0.38	86%	<0.001		
irregular vs regular	0.18	0.01–0.46	82%	<0.001	0.28	0.00-0.82	72%	0.070		

Table S1

i-ENR model with probabilistic stop on infection. Stop probability: 0.30 (irregular), 0.05 (regular). Statistics for hospitalisations and deaths are reported for all individuals in the cohort.

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.83	0.80-0.88	17%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	1.18	1.11–1.25	-18%	1.000	0.68	0.64–0.72	32%	<0.001		
non-user vs regular	0.45	0.39–0.52	55%	<0.001	0.51	0.45–0.58	49%	<0.001		
irregular vs regular	0.38	0.33–0.44	62%	<0.001	0.75	0.66–0.85	25%	<0.001		
Hospitalisation										
non-user vs user	0.75	0.56–1.03	25%	0.039	0.35	0.26-0.46	65%	< 0.001		
non-user vs irregular	1.30	0.92–1.86	-30%	0.915	0.52	0.35–0.73	48%	<0.001		
non-user vs regular	0.32	0.06–0.71	68%	0.002	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.25	0.04–0.56	75%	<0.001	0.00	0.00-0.00	100%	<0.001		
Death										
non-user vs user	0.71	0.50–1.02	29%	0.026	0.32	0.22-0.44	68%	<0.001		
non-user vs irregular	1.35	0.91–2.01	-35%	0.926	0.49	0.32-0.74	51%	<0.001		
non-user vs regular	0.21	0.01–0.55	79%	0.001	0.14	0.00-0.38	86%	<0.001		
irregular vs regular	0.16	0.01–0.41	84%	<0.001	0.28	0.00-0.78	72%	0.070		

i-ENR model with uniform stop on infection. Stop probability: 1.0 (all individuals). Statistics for hospitalisations and deaths are reported for all individuals in the cohort.

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.83	0.80-0.88	17%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	0.94	0.88–1.00	6%	0.022	0.68	0.64–0.72	32%	<0.001		
non-user vs regular	0.72	0.64–0.81	28%	<0.001	0.51	0.45–0.58	49%	<0.001		
irregular vs regular	0.77	0.68–0.86	23%	<0.001	0.75	0.66–0.85	25%	<0.001		
Hospitalisation										
non-user vs user	0.90	0.67–1.23	10%	0.217	0.63	0.47–0.83	37%	0.001		
non-user vs irregular	1.31	0.92–1.86	-31%	0.916	0.76	0.51–1.08	24%	0.143		
non-user vs regular	0.45	0.09–1.00	55%	0.034	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.35	0.07–0.78	65%	0.001	0.00	0.00-0.00	100%	0.003		
Death										
non-user vs user	0.85	0.61–1.22	15%	0.150	0.57	0.40-0.80	43%	<0.001		
non-user vs irregular	1.34	0.90–2.00	-34%	0.907	0.72	0.45–1.07	28%	0.149		
non-user vs regular	0.31	0.02–0.78	69%	0.005	0.27	0.00-0.74	73%	0.044		
irregular vs regular	0.23	0.02–0.60	77%	<0.001	0.38	0.00–1.09	62%	0.212		

Table S3

i-ENR model with probabilistic stop on infection. Stop probability: 0.30 (irregular), 0.05 (regular). Statistics for hospitalisations and deaths are limited to infected individuals.

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.83	0.80-0.88	17%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	1.18	1.11–1.25	-18%	1.000	0.68	0.65–0.73	32%	<0.001		
non-user vs regular	0.45	0.39–0.52	55%	<0.001	0.51	0.45–0.58	49%	<0.001		
irregular vs regular	0.38	0.33–0.44	62%	<0.001	0.75	0.66–0.84	25%	<0.001		
Hospitalisation										
non-user vs user	0.90	0.67–1.23	10%	0.217	0.63	0.47–0.83	37%	0.001		
non-user vs irregular	1.11	0.78–1.56	-11%	0.687	0.76	0.50–1.07	24%	0.143		
non-user vs regular	0.71	0.13–1.57	29%	0.215	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.65	0.12–1.44	35%	0.168	0.00	0.00-0.00	100%	0.003		
Death										
non-user vs user	0.85	0.61–1.22	15%	0.150	0.57	0.41–0.79	43%	<0.001		
non-user vs irregular	1.15	0.78–1.69	-15%	0.723	0.72	0.45–1.07	28%	0.149		
non-user vs regular	0.46	0.03–1.20	54%	0.084	0.27	0.00-0.71	73%	0.044		
irregular vs regular	0.41	0.03–1.07	59%	0.046	0.38	0.00–1.09	62%	0.212		

i-ENR model with uniform stop on infection. Stop probability: 1.0 (all individuals). Statistics for hospitalisations and deaths are limited to infected individuals.

i-INF model simulations

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.73	0.70–0.76	27%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	0.82	0.77–0.87	18%	<0.001	0.68	0.64–0.72	32%	<0.001		
non-user vs regular	0.63	0.55–0.70	37%	<0.001	0.51	0.45–0.57	49%	<0.001		
irregular vs regular	0.76	0.67–0.86	24%	<0.001	0.75	0.66–0.84	25%	<0.001		
Hospitalisation										
non-user vs user	0.59	0.44-0.80	41%	<0.001	0.35	0.26-0.47	65%	<0.001		
non-user vs irregular	0.97	0.67–1.37	3%	0.380	0.52	0.35–0.74	48%	<0.001		
non-user vs regular	0.25	0.04–0.56	75%	<0.001	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.26	0.04–0.61	74%	0.001	0.00	0.00-0.00	100%	<0.001		
Death										
non-user vs user	0.54	0.39–0.77	46%	0.002	0.32	0.22-0.44	68%	<0.001		
non-user vs irregular	0.97	0.64–1.43	3%	0.384	0.49	0.31–0.75	51%	<0.001		
non-user vs regular	0.16	0.01-0.42	84%	<0.001	0.14	0.00–0.39	86%	<0.001		
irregular vs regular	0.17	0.01–0.46	83%	<0.001	0.28	0.00-0.82	72%	0.070		

Table S5

i-INF model with probabilistic stop on infection. Stop probability: 0.30 (irregular), 0.05 (regular). Statistics for hospitalisations and deaths are reported for all individuals in the cohort.

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.73	0.70–0.76	27%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	1.03	0.98–1.09	-3%	0.867	0.68	0.64–0.73	32%	<0.001		
non-user vs regular	0.39	0.33–0.45	61%	<0.001	0.51	0.45-0.58	49%	<0.001		
irregular vs regular	0.38	0.32-0.44	62%	<0.001	0.75	0.66–0.85	25%	<0.001		
Hospitalisation										
non-user vs user	0.59	0.44-0.80	41%	<0.001	0.35	0.26-0.46	65%	<0.001		
non-user vs irregular	1.02	0.72–1.44	-2%	0.509	0.52	0.35–0.74	48%	<0.001		
non-user vs regular	0.24	0.04–0.56	76%	<0.001	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.24	0.04–0.56	76%	<0.001	0.00	0.00-0.00	100%	<0.001		
Death										
non-user vs user	0.54	0.39–0.77	46%	0.002	0.32	0.22-0.45	68%	<0.001		
non-user vs irregular	1.04	0.70–1.52	-4%	0.527	0.49	0.31–0.74	51%	<0.001		
non-user vs regular	0.15	0.01-0.40	85%	<0.001	0.14	0.00-0.38	86%	<0.001		
irregular vs regular	0.15	0.01–0.41	85%	<0.001	0.28	0.00-0.82	72%	0.070		

i-INF model with uniform stop on infection. Stop probability: 1.0 (all individuals). Statistics for hospitalisations and deaths are reported for all individuals in the cohort.

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.73	0.70–0.76	27%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	0.82	0.77–0.87	18%	<0.001	0.68	0.64–0.73	32%	<0.001		
non-user vs regular	0.63	0.55–0.70	37%	<0.001	0.51	0.45–0.57	49%	<0.001		
irregular vs regular	0.76	0.67–0.86	24%	<0.001	0.75	0.66–0.85	25%	<0.001		
Hospitalisation										
non-user vs user	0.81	0.61–1.09	19%	0.066	0.63	0.47–0.83	37%	0.001		
non-user vs irregular	1.18	0.82–1.65	-18%	0.798	0.76	0.51–1.07	24%	0.143		
non-user vs regular	0.40	0.06–0.89	60%	0.018	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.35	0.06–0.79	65%	0.005	0.00	0.00-0.00	100%	0.003		
Death										
non-user vs user	0.74	0.53–1.05	26%	0.040	0.57	0.40-0.79	43%	<0.001		
non-user vs irregular	1.17	0.79–1.73	-17%	0.766	0.72	0.46–1.07	28%	0.149		
non-user vs regular	0.26	0.01–0.67	74%	0.003	0.27	0.00–0.71	73%	0.044		
irregular vs regular	0.22	0.01–0.60	78%	0.002	0.38	0.00–1.05	62%	0.212		

Table S7

i-INF model with probabilistic stop on infection. Stop probability: 0.30 (irregular), 0.05 (regular). Statistics for hospitalisations and deaths are limited to infected individuals.

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.73	0.70–0.76	27%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	1.03	0.98–1.09	-3%	0.867	0.68	0.65–0.73	32%	<0.001		
non-user vs regular	0.39	0.33–0.45	61%	<0.001	0.51	0.45–0.58	49%	<0.001		
irregular vs regular	0.38	0.32-0.44	62%	<0.001	0.75	0.66–0.85	25%	<0.001		
Hospitalisation										
non-user vs user	0.81	0.61–1.09	19%	0.066	0.63	0.47–0.83	37%	0.001		
non-user vs irregular	0.99	0.70–1.39	1%	0.436	0.76	0.51–1.08	24%	0.143		
non-user vs regular	0.62	0.10–1.41	38%	0.147	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.64	0.10–1.46	36%	0.153	0.00	0.00-0.00	100%	0.003		
Death										
non-user vs user	0.74	0.53–1.05	26%	0.040	0.57	0.41–0.79	43%	<0.001		
non-user vs irregular	1.00	0.68–1.46	-0%	0.464	0.72	0.45–1.08	28%	0.149		
non-user vs regular	0.38	0.02-1.02	62%	0.041	0.27	0.00-0.74	73%	0.044		
irregular vs regular	0.39	0.02–1.06	61%	0.047	0.38	0.00–1.05	62%	0.212		

i-INF model with uniform stop on infection. Stop probability: 1.0 (all individuals). Statistics for hospitalisations and deaths are limited to infected individuals.

i-KC22 model simulations

		Simulation				KB22/KC22				
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val		
Infection										
non-user vs user	0.49	0.47–0.51	51%	<0.001	0.56	0.53–0.58	44%	<0.001		
non-user vs irregular	0.64	0.60–0.68	36%	<0.001	0.68	0.64–0.73	32%	<0.001		
non-user vs regular	0.37	0.33–0.43	63%	<0.001	0.51	0.45–0.57	49%	<0.001		
irregular vs regular	0.59	0.51–0.67	41%	<0.001	0.75	0.66–0.85	25%	<0.001		
Hospitalisation										
non-user vs user	0.40	0.28–0.56	60%	<0.001	0.35	0.26-0.47	65%	<0.001		
non-user vs irregular	0.74	0.49–1.09	26%	0.045	0.52	0.34–0.74	48%	<0.001		
non-user vs regular	0.15	0.01–0.39	85%	< 0.001	0.00	0.00-0.00	100%	<0.001		
irregular vs regular	0.21	0.01–0.56	79%	<0.001	0.00	0.00-0.00	100%	<0.001		
Death										
non-user vs user	0.34	0.24-0.47	66%	<0.001	0.32	0.22-0.44	68%	<0.001		
non-user vs irregular	0.67	0.45-0.98	33%	0.018	0.49	0.31–0.74	51%	<0.001		
non-user vs regular	0.08	0.00-0.23	92%	<0.001	0.14	0.00-0.38	86%	<0.001		
irregular vs regular	0.13	0.00-0.37	87%	<0.001	0.28	0.00–0.79	72%	0.070		

Table S9

i-KC22 model with probabilistic stop on infection. Stop probability: 0.30 (irregular), 0.05 (regular). Statistics for hospitalisations and deaths are reported for all individuals in the cohort.

	Simulation				KB22/KC22			
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val
Infection								
non-user vs user	0.49	0.47–0.51	51%	<0.001	0.56	0.53–0.58	44%	<0.001
non-user vs irregular	1.00	0.95–1.05	0%	0.450	0.68	0.64–0.73	32%	< 0.001
non-user vs regular	0.10	0.07–0.12	90%	<0.001	0.51	0.45-0.58	49%	< 0.001
irregular vs regular	0.10	0.07–0.12	90%	<0.001	0.75	0.66–0.85	25%	<0.001
Hospitalisation								
non-user vs user	0.40	0.28–0.56	60%	<0.001	0.35	0.26-0.47	65%	<0.001
non-user vs irregular	0.76	0.51–1.11	24%	0.062	0.52	0.34–0.73	48%	< 0.001
non-user vs regular	0.14	0.01–0.37	86%	<0.001	0.00	0.00-0.00	100%	<0.001
irregular vs regular	0.19	0.01–0.52	81%	<0.001	0.00	0.00-0.00	100%	<0.001
Death								
non-user vs user	0.34	0.24–0.47	66%	<0.001	0.32	0.23-0.44	68%	<0.001
non-user vs irregular	0.70	0.47–1.01	30%	0.023	0.49	0.31–0.74	51%	< 0.001
non-user vs regular	0.08	0.00-0.22	92%	<0.001	0.14	0.00-0.37	86%	<0.001
irregular vs regular	0.11	0.00-0.33	89%	<0.001	0.28	0.00-0.82	72%	0.070

i-KC22 model with uniform stop on infection. Stop probability: 1.0 (all individuals). Statistics for hospitalisations and deaths are reported for all individuals in the cohort.

	Simulation				KB22/KC22				
Summary statistics	RR	95% Cl	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val	
Infection									
non-user vs user	0.49	0.47–0.51	51%	<0.001	0.56	0.53–0.58	44%	<0.001	
non-user vs irregular	0.64	0.60-0.68	36%	<0.001	0.68	0.64–0.72	32%	<0.001	
non-user vs regular	0.37	0.33–0.43	63%	<0.001	0.51	0.45–0.58	49%	<0.001	
irregular vs regular	0.59	0.51–0.67	41%	<0.001	0.75	0.66–0.85	25%	<0.001	
Hospitalisation									
non-user vs user	0.82	0.58–1.14	18%	0.100	0.63	0.48-0.83	37%	0.001	
non-user vs irregular	1.15	0.76–1.69	-15%	0.734	0.76	0.50–1.08	24%	0.143	
non-user vs regular	0.40	0.02-1.02	60%	0.038	0.00	0.00-0.00	100%	<0.001	
irregular vs regular	0.35	0.02–0.94	65%	0.015	0.00	0.00-0.00	100%	0.003	
Death									
non-user vs user	0.69	0.49–0.96	31%	0.011	0.57	0.40-0.78	43%	<0.001	
non-user vs irregular	1.05	0.70–1.52	-5%	0.586	0.72	0.46–1.07	28%	0.149	
non-user vs regular	0.22	0.01–0.61	78%	0.005	0.27	0.00-0.74	73%	0.044	
irregular vs regular	0.21	0.01-0.62	79%	0.004	0.38	0.00–1.09	62%	0.212	

Table S11

i-KC22 model with probabilistic stop on infection. Stop probability: 0.30 (irregular), 0.05 (regular). Statistics for hospitalisations and deaths are limited to infected individuals.

	Simulation				KB22/KC22			
Summary statistics	RR	95% CI	Risk Red.	p.val	RR	95% CI	Risk Red.	p.val
Infection								
non-user vs user	0.49	0.47–0.51	51%	<0.001	0.56	0.53–0.58	44%	<0.001
non-user vs irregular	1.00	0.95–1.05	0%	0.450	0.68	0.64–0.72	32%	<0.001
non-user vs regular	0.10	0.07-0.12	90%	<0.001	0.51	0.45–0.57	49%	<0.001
irregular vs regular	0.10	0.07–0.12	90%	<0.001	0.75	0.66–0.85	25%	<0.001
Hospitalisation								
non-user vs user	0.82	0.58–1.14	18%	0.100	0.63	0.47–0.84	37%	0.001
non-user vs irregular	0.76	0.51–1.11	24%	0.067	0.76	0.50–1.05	24%	0.143
non-user vs regular	1.48	0.07–3.84	-48%	0.579	0.00	0.00-0.00	100%	<0.001
irregular vs regular	1.97	0.08–5.30	-97%	0.768	0.00	0.00-0.00	100%	0.003
Death								
non-user vs user	0.69	0.49–0.96	31%	0.011	0.57	0.41–0.78	43%	<0.001
non-user vs irregular	0.70	0.47–1.01	30%	0.023	0.72	0.45–1.07	28%	0.149
non-user vs regular	0.79	0.02-2.24	21%	0.301	0.27	0.00-0.71	73%	0.044
irregular vs regular	1.15	0.02-3.37	-15%	0.539	0.38	0.00–1.05	62%	0.212

i-KC22 model with uniform stop on infection. Stop probability: 1.0 (all individuals). Statistics for hospitalisations and deaths are limited to infected individuals.

Supplemental Figures



Figure S1

"Missed" deaths. Event dates for missed Covid deaths after symptom onset during the study period based on matching the SUS data from KC22. The three sub-panels show recorded dates of symptom onset, hospitalisation, and death.



Figure S2

Attrition bias in the i-INF model. A. Empirical distributions of simulated infection dates over 1000 runs of the i-INF model. Note the delayed early peak of infections in the ivermectin user group. B. Example from one typical simulation of uncounted deaths among ivermectin users. Each line segment represents an individual in the simulation who was infected and later died, with infection and death dates at the end points. The study end date is marked with a vertical line. C. Hospitalisations and deaths are lost to attrition more frequently in the user group (1000 simulations). D. The ivermectin user group has apparent (but fictitious) protection from hospitalisation and death compared to non-users.



Figure S3

Attrition bias in the i-KC22 model. A. Empirical distributions of simulated infection dates over 1000 runs of the modified i-KC22 model including late events. Note the delayed early peak of infections in the ivermectin user group. B. Example from one typical simulation of uncounted deaths among ivermectin users. Each line segment represents an individual in the simulation who was infected and later died, with infection and death dates at the end points. The study end date is marked with a vertical line. C. Hospitalisations and deaths are lost to attrition more frequently in the user group (1000 simulations). D. The ivermectin user group has apparent (but fictitious) protection from hospitalisation and death compared to non-users.



Immortal time bias protection of infected 'regular' users

Figure S4

Apparent protection of "regular" users in the i-INF model. A. Simulated dates of hospitalisation in i-INF for individuals grouped by exposure according to KB22-defined usage groups. The study end date is marked with a vertical line. B. Dates of death. C. Relative risk of hospitalisation and death for "regular" ivermectin users compared to "irregular" and non-users. Risk ratios are calculated and plotted for each of 1000 simulations. Dates of hospitalisation and death are shown for all individuals across 1000 simulations.



Immortal time bias protection of infected 'regular' users

Figure S5

Apparent protection of "regular" users in the i-KC22 model. A. Simulated dates of hospitalisation in i-INF for individuals grouped by exposure according to KB22-defined usage groups. The study end date is marked with a vertical line. B. Dates of death. C. Relative risk of hospitalisation and death for "regular" ivermectin users compared to "irregular" and non-users. Risk ratios are calculated and plotted for each of 1000 simulations. Dates of hospitalisation and death are shown for all individuals across 1000 simulations.